AR052837A1 - Composiciones que contienen hierro - Google Patents

Composiciones que contienen hierro

Info

Publication number
AR052837A1
AR052837A1 ARP050105442A ARP050105442A AR052837A1 AR 052837 A1 AR052837 A1 AR 052837A1 AR P050105442 A ARP050105442 A AR P050105442A AR P050105442 A ARP050105442 A AR P050105442A AR 052837 A1 AR052837 A1 AR 052837A1
Authority
AR
Argentina
Prior art keywords
iron
compositions
nutritional
promote
approximately
Prior art date
Application number
ARP050105442A
Other languages
English (en)
Inventor
Jonathan D Bortz
David S Hermelin
Mitchell I Kirschner
Original Assignee
Drug Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Drug Tech Corp filed Critical Drug Tech Corp
Publication of AR052837A1 publication Critical patent/AR052837A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Addiction (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)

Abstract

Composiciones de suplementos nutricionales o dietarios que promueven y/o mantienen la absorcion de hierro por la dieta mediante la administracion de hierro con un ácido orgánico y opcionalmente con promotores similares de la absorcion de hierro. Se proveen además métodos de suplementacion nutricional o dietaria utilizando una o más composiciones que promueven y/o mantienen la salud mediante la prevencion, estabilizacion, reversion y/o tratamiento de enfermedades asociadas con la deficiencia de hierro. Reivindicacion 1: Una composicion, caracterizada porque comprende: entre aproximadamente 10 mg. y aproximadamente 500 mg. de una o más formas de hierro; y entre aproximadamente 5 mg. y aproximadamente 500 mg. de una o más formas de un ácido orgánico, para administrar y así prevenir, estabilizar, revertir o tratar enfermedades relacionadas con la deficiencia de hierro en humanos u otros animales.
ARP050105442A 2004-12-22 2005-12-21 Composiciones que contienen hierro AR052837A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/020,801 US20060134227A1 (en) 2004-12-22 2004-12-22 Compositions including iron

Publications (1)

Publication Number Publication Date
AR052837A1 true AR052837A1 (es) 2007-04-04

Family

ID=36596132

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105442A AR052837A1 (es) 2004-12-22 2005-12-21 Composiciones que contienen hierro

Country Status (11)

Country Link
US (5) US20060134227A1 (es)
EP (2) EP1827418A4 (es)
JP (2) JP2008525442A (es)
CN (1) CN101102762A (es)
AR (1) AR052837A1 (es)
AU (1) AU2005319679A1 (es)
BR (1) BRPI0519265A2 (es)
CA (1) CA2591996A1 (es)
MX (1) MX2007008021A (es)
PE (1) PE20061122A1 (es)
WO (2) WO2006068697A2 (es)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10249552A1 (de) 2002-10-23 2004-05-13 Vifor (International) Ag Wasserlösliche Eisen-Kohlenhydrat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel
US20070065542A1 (en) * 2005-09-20 2007-03-22 Board Of Regents, The University Of Texas System Enhanced solubility of preformed calcium citrate by adding citric acid
CA2625375A1 (en) * 2005-10-11 2007-04-19 Bayer Consumer Care Ag Mixture of iron and copper salts masking mettalic taste
EP1790356A1 (de) * 2005-11-24 2007-05-30 Vifor (International) Ag Präparat, umfassend Eisen(III)-Komplexverbindungen und redoxaktive Substanz(en)
EP2626074A1 (en) 2006-01-06 2013-08-14 Luitpold Pharmaceuticals, Inc. Methods and compositions for administration of iron
CA2664406A1 (en) * 2006-09-28 2008-04-03 Bayer Consumer Care Ag Mixture of iron and copper salts masking metallic taste
US8178132B2 (en) 2007-03-22 2012-05-15 Magceutics, Inc. Magnesium-containing food compositions
ES2769583T3 (es) * 2007-03-22 2020-06-26 Neurocentria Inc Composiciones de magnesio y usos de las mismas
US7816404B2 (en) 2007-07-20 2010-10-19 Rockwell Medical Technologies, Inc. Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions
US20090047362A1 (en) * 2007-08-13 2009-02-19 Keith Edward Forrester Method for in-vitro stabilization of heavy metals
US7964189B1 (en) 2007-09-25 2011-06-21 Argent Development Group, Llc Nutritional supplements for women desiring to become pregnant, and pregnant and nursing women
US9125844B1 (en) 2007-09-25 2015-09-08 Argent Development Group, Llc Nutritional supplements for women desiring to become pregnant, and pregnant and nursing women
ITMI20071979A1 (it) * 2007-10-12 2009-04-13 Massimo Baldacci Formulazioni farmaceutiche contenenti ferro bisglicinato chelato
US20090124572A1 (en) * 2007-11-09 2009-05-14 Deanna Jean Nelson Iron-containing nutritional supplement
US8535660B1 (en) 2008-05-27 2013-09-17 Argent Development Group, Llc Nutritional supplements for pregnant women
US8535659B1 (en) 2008-05-27 2013-09-17 Argent Development Group, Llc Nutritional supplements for pregnant women
CN102159205A (zh) 2008-06-25 2011-08-17 Fe3医学有限公司 用于经皮递送治疗有效量的铁的贴片和方法
WO2010036977A2 (en) * 2008-09-25 2010-04-01 New England Medical Center Hospitals, Inc. Combination therapies with topiramate for seizures, restless legs syndrome, and other neurological conditions
US8202830B2 (en) 2009-01-30 2012-06-19 Ecolab Usa Inc. Development of an aluminum hydroxydicarboxylate builder
EP3399014B1 (en) * 2009-01-30 2020-02-26 Ecolab USA Inc. Development of an aluminum hydroxycarboxylate builder
US8821945B2 (en) 2009-04-25 2014-09-02 Fe3 Medical, Inc. Method for transdermal iontophoretic delivery of chelated agents
WO2010136839A1 (en) * 2009-05-29 2010-12-02 Carlo Ghisalberti Use of deferoxamine and related compounds in targeted delivery forms to treat an inflammatory bowel disease
KR20120046753A (ko) 2009-07-21 2012-05-10 케릭스 바이오파마슈티컬스 인코포레이티드 구연산철 투여형태
US8178709B2 (en) * 2009-07-21 2012-05-15 Biolink Life Sciences, Inc. Iron preparation suitable for pharmaceutical formulation and process for the preparation thereof
US8536106B2 (en) 2010-04-14 2013-09-17 Ecolab Usa Inc. Ferric hydroxycarboxylate as a builder
JP5357102B2 (ja) * 2010-04-27 2013-12-04 日本炉機工業株式会社 石化遺骨灰の製造方法
EP2420243A1 (en) 2010-08-18 2012-02-22 Inovativo Biomedicinas Tehnologiju Instituts, SIA Compositions obtainable from bred beetroot juice to promote iron absorption and blood forming
IT1402142B1 (it) * 2010-09-24 2013-08-28 Just Pharma S R L Formulazione integrativa finalizzata al controllo delle alterazioni multifattoriali ricorrenti nell'anemia da carenza di ferro e per colmare eventuali carenze o aumentati fabbisogni nutrizionali in alcune condizioni fisiopatologiche.
EP2497380A1 (en) * 2011-03-10 2012-09-12 DSM IP Assets B.V. Process for iron supplementation of beverages
ES2548407T3 (es) 2011-05-31 2015-10-16 Vifor (International) Ag Compuestos de complejos de 2,4-dioxo-1-carbonilo de Fe(III) para su uso en el tratamiento y la profilaxis de estados de deficiencia de hierro y anemias por deficiencia de hierro
BR112014007022B1 (pt) * 2011-09-22 2021-02-09 Amip composição farmacêutica, método e uso de uma composição farmacêutica
CN104884055A (zh) * 2012-06-21 2015-09-02 凯克斯生物制药公司 柠檬酸铁在治疗慢性肾脏疾病患者中的应用
US20150250839A1 (en) * 2012-09-11 2015-09-10 Dakota Star Capital Llc Nutritional supplement containing iron
CN102961338B (zh) * 2012-12-07 2015-03-18 青岛黄海制药有限责任公司 一种多糖铁缓释微丸制剂及其制备方法
EP3003328B1 (en) 2013-06-06 2021-07-28 Albion Laboratories, Inc. Iron supplement
ES2683212T3 (es) * 2013-08-28 2018-09-25 Dsm Ip Assets B.V. Complementación de hierro de un concentrado de caldo
PL3048903T3 (pl) * 2013-08-28 2017-09-29 Dsm Ip Assets B.V. Suplementacja żelaza koncentratu bulionu
AU2013400082B2 (en) * 2013-09-05 2016-01-28 Profeat Biotechnology Co., Ltd. Use of composition containing ferrous amino acid chelate in preparation of anti-cancer medicament
TWI483721B (zh) 2013-09-05 2015-05-11 Profeat Biotechnology Co Ltd The use of a composition containing a ferrous amino acid chelate for the manufacture of anti-cancer medicaments
US9629846B1 (en) 2013-11-14 2017-04-25 Argent Development Group, Llc Nutritional supplements for women desiring to become pregnant, and pregnant and nursing women
US9492421B1 (en) 2013-11-14 2016-11-15 Argent Development Group, Llc Nutritional supplements for treatment of iron deficiency anemia
CN104644557B (zh) * 2013-11-22 2017-10-31 上海宣泰医药科技有限公司 卟啉铁固体分散体及其制备方法
JP2014051535A (ja) * 2013-12-19 2014-03-20 Fujifilm Corp 鉄、カルシウム、又はマグネシウムの吸収を促進する方法
CN104887696B (zh) * 2014-03-04 2018-06-29 天津怀仁制药有限公司 右旋糖酐铁和维生素c的复方制剂
EP3179249A4 (en) * 2014-08-05 2017-07-26 Fujifilm Corporation Nucleated erythrocyte sorting method
EP3179870B1 (en) 2014-08-13 2023-10-04 Akeso Biomedical Inc. Antimicrobial compounds and compositions, and uses thereof
GB201416293D0 (en) * 2014-09-15 2014-10-29 Solvotrin Therapeutics Ltd Methods and preparations
JP5757493B1 (ja) * 2014-09-24 2015-07-29 富田製薬株式会社 経口型鉄分補給用固形組成物及びその製造方法
EP3216782B1 (en) * 2014-11-07 2021-06-02 NPA - Núcleo De Pesquisas Aplicadas LTDA. Iron amino acid compounds, method for preparing iron amino acid compounds, compositions containing iron amino acid compounds, and uses thereof
JP6440843B2 (ja) 2014-12-01 2018-12-19 普惠徳生技股▲ふん▼有限公司 脂肪代謝の調節に供する医薬品の製造のための第一鉄アミノ酸キレートを含む組成物の使用
CN104474004A (zh) * 2014-12-09 2015-04-01 重庆综艺营养科技有限责任公司 改善贫血的赖氨酸螯合铁生血素
US20170360075A1 (en) * 2014-12-11 2017-12-21 The Penn State Research Foundation Medical food for the treatment of malaria and/or iron deficiency
PL3334440T3 (pl) 2015-08-11 2021-11-02 Akeso Biomedical, Inc. Kompozycje hamujące tworzenie biofilmu wspierające przyrost masy ciała u zwierząt gospodarskich
US10653658B2 (en) 2015-08-11 2020-05-19 Akeso Biomedical, Inc. Biofilm inhibiting compositions enhancing weight gain in livestock
CN105476953B (zh) * 2015-09-01 2018-10-30 张伟 一种用于补铁的液体制剂及其制备方法
KR20180050346A (ko) * 2015-09-04 2018-05-14 락웰 메디컬, 인코포레이티드 가용성 고체 피로인산제2철(Soluble Ferric Pyrophosphate) 제제, 키트 및 이를 사용하는 방법
JP6919117B2 (ja) * 2015-12-15 2021-08-18 三菱ケミカル株式会社 鉄化合物含有組成物の粒子、鉄化合物の変色抑制方法、並びに鉄化合物及びビタミンｃ含有組成物
EP3199167A1 (de) * 2016-01-28 2017-08-02 G.L. Pharma GmbH Arzneimittel zur behandlung von eisenmangelzuständen mit folsäuredefizit
MA43703A (fr) * 2016-03-15 2018-11-28 Solvotrin Therapeutics Ltd Compositions et procédés permettant d'augmenter l'absorption de fer chez un mammifère
DK3459550T3 (da) * 2016-05-20 2021-10-04 Obshestvo S Ogranichennoj Otvetstvennostju Vikzdorove Zhivotnyh Ininjektionssammensætning omfattende et jerndextrankompleks og vitaminer til forebyggelse og behandling af anæmi
EP3466434A4 (en) * 2016-05-26 2020-01-22 Profeat Biotechnology Co. Ltd. USE OF A COMPOSITION WITH FERROUS AMINO ACID CHELATE FOR PRODUCING A MEDICINAL PRODUCT FOR REDUCING LACTIC ACID
CN106265731B (zh) * 2016-09-30 2019-07-19 广西科技大学 硫酸亚铁骨架型缓释滴丸的制备方法
US20190365697A1 (en) * 2017-02-17 2019-12-05 Profeat Biotechnology Co., Ltd. Method for Treating Liver Dysfunction
JP7426927B2 (ja) * 2017-09-11 2024-02-02 ファーマコスモス ホールディング エー／エス 治療的使用のための鉄錯体化合
CN108635370A (zh) * 2018-07-13 2018-10-12 山东达因海洋生物制药股份有限公司 一种含有右旋糖酐铁的组合物制剂及其制备方法
CN110464011A (zh) * 2018-08-07 2019-11-19 美安康质量检测技术（上海）有限公司 一种补血营养粉及其制备方法
JP2022504310A (ja) * 2018-10-05 2022-01-13 アンパサンド バイオファーマシューティカルズ インコーポレイテッド 局所投与のための鉄製剤および鉄欠乏症の処置の方法
EP3873493A4 (en) * 2018-10-31 2023-04-19 My-Or Diagnostics Ltd. PERSONALIZED FOODS TO ENSURE ADEQUATE IRON ABSORPTION
AU2018454589A1 (en) * 2018-12-20 2020-08-06 Profeat Biotechnology Co., Ltd. Composition comprising ferrous amino acid particles and method for treating or ameliorating pancreas-related disease using the same
WO2020125464A1 (zh) * 2018-12-20 2020-06-25 普惠德生技股份有限公司 含有亚铁胺基酸螯合物粒子的组合物用于制备治疗或减缓自体免疫相关疾病的医药品的用途
CN112168843A (zh) * 2019-07-05 2021-01-05 普惠德生技股份有限公司 经烧结的纳米粒子及其抗病毒的用途
US20230012448A1 (en) * 2021-06-30 2023-01-12 Getwing Biotechnology Medical Co., Ltd Methods for alleviating kidney disease and fibrosis of organ
WO2023272693A1 (zh) * 2021-07-01 2023-01-05 思瑰瑞保健食品有限公司 一种维生素c加硫酸亚铁缓控释片及其制备方法
WO2023023029A1 (en) * 2021-08-16 2023-02-23 Thermolife International, Llc Iron supplement compositions and methods of use thereof
CN114028423B (zh) * 2021-12-13 2023-05-23 广东粤港澳大湾区国家纳米科技创新研究院 修饰的纳米氧化铁在制备预防和/或治疗炎性肠病的药物中的应用
CN114288320A (zh) * 2021-12-29 2022-04-08 珠海天翼医药技术开发有限公司 一种猪用口服补铁剂及其制备方法
CN114767710B (zh) * 2022-04-12 2023-07-07 中山大学 甘氨酸亚铁在治疗类风湿关节炎中的应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB933108A (en) * 1960-02-03 1963-08-08 Haessle Ab Improvements in or relating to pharmaceutical iron preparations
GB1266356A (es) * 1968-08-08 1972-03-08
GB1292820A (en) * 1969-08-28 1972-10-11 Aspro Nicholas Ltd Haematinic preparations
GB1338071A (en) * 1970-11-25 1973-11-21 Laso Martinez V Pharmaceutical iron preparations
US3773929A (en) * 1972-11-02 1973-11-20 Diagnostic Data Inc Pharmaceutical compositions comprising orgotein and their use
US4362710A (en) * 1980-07-04 1982-12-07 Nissan Gosei Kogyo Co., Ltd. Feeds for baby pigs, process for preparing the same and method of breeding baby pigs
US4599152A (en) * 1985-05-24 1986-07-08 Albion Laboratories Pure amino acid chelates
US4863898A (en) * 1986-02-06 1989-09-05 Albion International, Inc. Amino acid chelated compositions for delivery to specific biological tissue sites
US4752479A (en) * 1986-05-27 1988-06-21 Ciba-Geigy Corporaton Multi vitamin and mineral dietary supplement with controlled release bioavailable iron
US4830716B1 (en) * 1986-07-03 1999-12-07 Albion Int Preparation of pharmaceutical grade amino acid chelates
US4822816A (en) * 1987-04-10 1989-04-18 Oxycal Laboratories, Inc. Compositions and methods for administering vitamin C
US5070085A (en) * 1987-04-10 1991-12-03 Oxycal Laboratories, Inc. Compositions and methods for administering therapeutically active compounds
FR2642420B1 (fr) * 1989-01-27 1991-09-06 Valpan Sa Labo Pharma Nouvelle forme galenique a liberation programmee contenant une association de sels ferreux, d'acide succinique et d'acide ascorbique
JPH0674206B2 (ja) * 1989-12-28 1994-09-21 田辺製薬株式会社 放出制御型製剤およびその製法
US6451341B1 (en) * 1990-02-05 2002-09-17 Thomas J. Slaga Time release formulation of vitamins, minerals and other beneficial supplements
HU207799B (en) * 1991-07-24 1993-06-28 Beres Export Import Rt Process for producing pharmaceutical composition for influencing the reticuloendothelial system, for treating chronic pain symptomes of degenerative locomotor disorders or tumors, and for treating mucoviscidosis
US5662922A (en) * 1992-01-20 1997-09-02 Christensen; Borge Holm Iron-containing composition for the prevention of anaemia and a method for producing the composition
US5516925A (en) * 1994-08-23 1996-05-14 Albion International, Inc. Amino acid chelates having improved palatability
JP2590449B2 (ja) * 1995-04-21 1997-03-12 農林水産省畜産試験場長 新生子牛の造血機能の改善及び貧血の予防方法
PT871378E (pt) * 1995-10-27 2002-11-29 Procter & Gamble Misturas secas para bebidas de cor estavel fortificadas com ferro zinco e vitaminas
US5770226A (en) * 1996-07-10 1998-06-23 Wake Forest University Combined pharmaceutical estrogen-androgen-progestin oral contraceptive
CA2230801A1 (en) * 1998-02-27 1999-08-27 Stanley H. Zlotkin Composition comprising micro-encapsulated iron
US6495177B1 (en) * 1999-08-13 2002-12-17 Warner Chilcott Laboratories Ireland Limited Orally dissolvable nutritional supplement
US6521247B1 (en) * 1999-08-13 2003-02-18 Warner Chilcott Laboratories Ireland Limited Dual iron containing nutritional supplement
CN1396908A (zh) * 2000-01-28 2003-02-12 宝洁公司 美味的精氨酸化合物及其用于心血管健康的应用
US20020013331A1 (en) * 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
US6924273B2 (en) * 2000-10-03 2005-08-02 Scott W. Pierce Chondroprotective/restorative compositions and methods of use thereof
US6716814B2 (en) * 2001-08-16 2004-04-06 Albion International, Inc. Enhancing solubility of iron amino acid chelates and iron proteinates
US6906038B2 (en) * 2001-08-29 2005-06-14 Abbott Laboratories Methods for alleviating mucositis
US20030190355A1 (en) * 2002-04-05 2003-10-09 Hermelin Marc S. Modified release minerals
US7994217B2 (en) * 2002-05-02 2011-08-09 Xanodyne Pharmaceuticals, Inc. Prenatal multivitamin/multimineral supplement
US20060148690A1 (en) * 2002-07-08 2006-07-06 Lydie Bougueleret Secreted peptides
US20030045473A1 (en) * 2002-07-19 2003-03-06 Sarama Robert Joseph Compositions, kits, and methods for cardiovascular health
US8007846B2 (en) * 2006-01-18 2011-08-30 Albion International, Inc. Mixed amino acid/mineral compounds having improved solubility

Also Published As

Publication number Publication date
EP1827418A2 (en) 2007-09-05
CA2591996A1 (en) 2006-06-29
WO2006068729A2 (en) 2006-06-29
US20090028962A1 (en) 2009-01-29
CN101102762A (zh) 2008-01-09
JP2008525442A (ja) 2008-07-17
MX2007008021A (es) 2008-04-11
US20160022631A1 (en) 2016-01-28
US20110015150A1 (en) 2011-01-20
AU2005319679A1 (en) 2006-06-29
EP1827419A2 (en) 2007-09-05
WO2006068697A2 (en) 2006-06-29
WO2006068697A3 (en) 2006-12-21
EP1827418A4 (en) 2011-08-24
BRPI0519265A2 (pt) 2009-01-06
US20060134227A1 (en) 2006-06-22
US20130189374A1 (en) 2013-07-25
JP2008525445A (ja) 2008-07-17
WO2006068729A3 (en) 2007-01-18
EP1827419A4 (en) 2011-08-17
PE20061122A1 (es) 2006-10-16

Similar Documents

Publication Publication Date Title
AR052837A1 (es) Composiciones que contienen hierro
MXPA04009765A (es) Metodo para mejorar la absorcion de la vitamina e por una mascota animal.
ATE508642T1 (de) Hydroxytyrosol-verstärkte öle und deren verwendung
HK1118455A1 (en) Combination comprising at least one amino acid and a pkr inhibitor for use in the treatment of muscle loss
AR064332A1 (es) Composicion suplementaria nutricional o dietetica que fortalece y promueve la salud retinal
MY176679A (en) Use of nutritional compositions for preventing disorders
ES2571856T3 (es) Uso de composiciones nutricionales para prevenir la adiposidad visceral
WO2004004599A3 (en) Epa and dha enriched omega-3 supplement for the treatment of dry eye, meibomianitis and xerostomia
WO2006017627A3 (en) Dietary compositions comprising docosahexaenoic acid and eicosapentaenoic acid and use thereof for treating insulin resistance
EP2241196A3 (en) Nutritional supplement comprising oligosaccharides and cysteine for treating hiv
PT1411960E (pt) Produto alimentar enriquecido a base de farelo de arroz para promocao da saude cardiovascular
MX2018014083A (es) Composiciones nutritivas para la proteccion cardiaca en animales de compañia.
BR112014009097A2 (pt) composição para uso na promoção de crescimento de osso saudável e/ou na prevenção e/ou tratamento das doenças dos ossos
CY1112660T1 (el) Συμπληρωμα διατροφης που παρεχει ενεργεια σε σκελετικους μυες και που προστατευει την καρδιαγγειακη οδο
DOP2006000208A (es) Suplementos nutricionales con fitosterol
DE602006011127D1 (de) Fettsäure-benzenediol-derivate sowie herstellungs- und verwendungsverfahren dafür
CY1108138T1 (el) Χρησιμοποιηση λουπινοκονγλουτινης δια την θεραπευτικη αγωγη διαβητου τυπου ιι
TW200724133A (en) Synergistic combinations
BR0210906A (pt) Método para aumento de eficiência de ruminantes
NO20081791L (no) Kombinasjon av metionin og minst ±n eterisk olje
AR076576A1 (es) Procedimiento para estabilizar un suplemento dietetico para facilitar la salud de las articulaciones en seres humanos
MX2021005534A (es) Metodos para aumentar la oxidacion de grasa o el gasto de energia o la saciedad en un animal.
RU2013133998A (ru) Способы и композиции для предотвращения и лечения остеоартрита
AR114427A1 (es) Una composición de alimento para rumiantes que comprende polipéptidos que tienen actividad de muramidasa y métodos para mejorar la digestibilidad en rumiantes
AR045853A1 (es) Metodo y composicion para mejorar la capacidad de aprender en un cachorro o gatito

Legal Events

Date Code Title Description
FB Suspension of granting procedure